ArriVent BioPharma, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2021-01-01
- Employees
- 40
- Market Cap
- $931M
- Website
- http://www.arrivent.com
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- ArriVent BioPharma, Inc.
- Target Recruit Count
- 375
- Registration Number
- NCT05607550
- Locations
- 🇬🇧
Arrivent Investigative Site, Bebington, Wirral, United Kingdom
🇺🇸Arrivent Investigative site, Sacramento, California, United States
🇬🇧ArriVent Investigative Site, Sutton, United Kingdom
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- ArriVent BioPharma, Inc.
- Target Recruit Count
- 170
- Registration Number
- NCT05364073
- Locations
- 🇬🇧
ArriVent Investigative Site, London, United Kingdom
🇳🇱Arrivent Investigative Site, Amsterdam, Noord-Holland, Netherlands
🇨🇳Allist Investigative Site, Taiyuan, Shanxi, China
© Copyright 2024. All Rights Reserved by MedPath